ASIT on the slide after trial setback

19 June 2017

ASIT Biotech (Euronext: ASIT) looked set to close almost 10% down after Monday’s trading at around 5.26 euros ($5.88) due to some bad news on its gp-ASIT+ candidate for the treatment of grass pollen rhinitis.

The Belgian company, which is focused on the research, development and future commercialization of breakthrough immunotherapy products for allergies, has reported comments from the German health authority the Paul Ehrlich Institute (PEI), and presented detailed Phase III results on gp-ASIT+ at the European Academy of Allergy and Clinical Immunology congress (EAACI 2017) in Helsinki.

"For this study, we had to deal with an atypical pollen season"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK